FDA approves labelling update for VIVUS’ QSYMIAThe FDA has approved a labelling update for VIVUS’ QSYMIA (phentermine and topiramate extended-release capsules CIV) that has removed the...
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events2 days ago